Shanghai Henlius Biotech, Inc.
Shanghai Henlius Biotech, Inc. (HKSE: 2696) is trading at HK$58.65, about ₹718 at today's HKD/INR rate, as of 30 Sep 2026, 4:08 AM ET, up 5.30% today. Indian residents can buy Shanghai Henlius Biotech from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
HK$55.65
Today's high
HK$59.00
52 week low
HK$50.25
52 week high
HK$87.10
2696 opened at HK$56.10, closed previously at HK$55.70, and has traded between HK$50.25 and HK$87.10 over the past 52 weeks.
About
Shanghai Henlius Biotech, Inc. functions as a biopharmaceutical enterprise, dedicated to the research and advancement of biologic medicines, with a primary focus on cancer, autoimmune conditions, and ophthalmic disorders. Its commercial portfolio encompasses several approved biologic treatments. Specifically, it markets HANLIKANG, a rituximab injection utilized for non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection indicated for breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection with indications in metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. In addition to its marketed products, Shanghai Henlius is actively progressing its robust development pipeline, which includes Serplulimab, undergoing further development for applications such as squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and a range of other solid tumor types. Among its other investigational compounds are HLX04-O, a bevacizumab injection aimed at wet age-related macular degeneration; HLX22 for breast and metastatic gastric cancer; a group of therapies—HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20—collectively aimed at solid tumors; HLX11 for breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12, addressing gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14, designed to treat osteoporosis. Further expanding its pipeline, HLX26 is being developed for solid tumors and lymphoma; HLX13 is under investigation for melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71, with potential for treating COVID-19. The firm conducts its operations across Mainland China, Europe, the broader Asia-Pacific region, and various other international territories. Founded in 2010, its headquarters are situated in Shanghai, China. Shanghai Henlius Biotech, Inc. operates as a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Key statistics
Avg. volume
971.76K
Market cap
HK$31.88B
P/E Ratio
31.53
Price-to-sales ratio
3.67
Enterprise value
CN¥30.80B
Free cash flow yield
3.07%
Debt-to-equity ratio
0.87
Return on equity
20.33%
ROIC
8.45%
Beta
0.51
Dividend yield
0.00%
Last dividend
HK$0.00
Financial overview
Revenue
CN¥6.67B
Earnings per share
CN¥1.47
Free cash flow
CN¥859.86M
Net profit margin
11.67%
Gross margin
74.69%
EBITDA
CN¥1.16B
Revenue growth
16.46%
Similar securities
This is not an investment recommendation
How to buy Shanghai Henlius Biotech from India
Indian residents can buy Shanghai Henlius Biotech shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars and then to HKD.
Search for Shanghai Henlius Biotech and place an order
Find Shanghai Henlius Biotech by name or by its ticker, 2696, and choose an order type. Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share. Shanghai Henlius Biotech trades 7:00 am – 1:30 pm IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Shanghai Henlius Biotech position in HKD and INR. Shanghai Henlius Biotech pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Shanghai Henlius Biotech from India
Trading and taxes when buying Shanghai Henlius Biotech from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm HKT
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneShanghai Henlius Biotech does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
Custody. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
FAQs
Can Indian residents buy Shanghai Henlius Biotech stock?
Yes. Shanghai Henlius Biotech (2696) has been listed on the Hong Kong Stock Exchange since 2019, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars and then to HKD. Shares are held in your own name at Interactive Brokers, segregated from Paasa's own assets.
How much does one Shanghai Henlius Biotech share cost in rupees?
One Shanghai Henlius Biotech share is HK$58.65 — about ₹718 at an HKD/INR rate of 12.24 on 29 Sep 2026. Both the Shanghai Henlius Biotech price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Shanghai Henlius Biotech from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
What is the minimum I can buy of Shanghai Henlius Biotech?
Many Hong Kong listings trade in board lots, so the smallest order is one lot rather than one share.
How are gains on Shanghai Henlius Biotech shares taxed in India?
Hong Kong generally does not levy capital gains tax on non-resident individual investors for HKEX-listed stocks, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the HKD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Shanghai Henlius Biotech price. Paasa issues a capital-gains statement for your return.
Does Shanghai Henlius Biotech pay a dividend?
No. Shanghai Henlius Biotech does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Shanghai Henlius Biotech from India?
The Hong Kong Stock Exchange trades 7:00 am – 1:30 pm IST in Indian time. It also halts for lunch, 9:30 am – 10:30 am IST. Orders can only execute during that window.
Is Shanghai Henlius Biotech a Hong Kong SAR China company, and does that change how it is taxed?
Shanghai Henlius Biotech trades on the Hong Kong Stock Exchange in HKD, but the company is domiciled in China. Shanghai Henlius Biotech trades as an ordinary share listed directly in Hong Kong, not a depositary receipt. Your India-side capital-gains treatment is the same either way.
Do I have to declare Shanghai Henlius Biotech shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Shanghai Henlius Biotech holding, its cost and its closing value.
How do I sell Shanghai Henlius Biotech and bring the money back to India?
You sell during market hours (7:00 am – 1:30 pm IST) and the proceeds settle in HKD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.